What is Gain Therapeutics Inc (GANX) stock price today?

Gain Therapeutics Inc (GANX) currently trades at $1.76 per share. The stock has a market capitalization of $83.70M and a P/E ratio of —x.

Is GANX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Gain Therapeutics Inc has a Smart Value Score of 18/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -12.79.

Is Gain Therapeutics Inc financially healthy?

Gain Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -12.79 places it in the distress.

GANX

Gain Therapeutics Inc

NASDAQ: GANX · HEALTHCARE · BIOTECHNOLOGY

$1.76

-4.86% today

Updated 2026-04-29

Market cap

$83.70M

P/E ratio

—

P/S ratio

255.50x

EPS (TTM)

$-0.61

Dividend yield

—

52W range

$1 – $4

Volume

0.7M

Market cap

$83.70M

P/E ratio

—

P/S ratio

255.50x

EPS (TTM)

$-0.61

Dividend yield

—

52W range

$1 – $4

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-12.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$7.60

+331.82%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -12.79 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-4.62M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$132640.00	$55180.00	$0.00	$0.00	$0.00
Net income	$-17.59M	$-22.27M	$-20.41M	$-20.16M	$-4.54M
EPS	—	—	—	—	$-0.61
Free cash flow	$-14.81M	$-18.88M	$-18.90M	$-18.47M	$-4.62M
Profit margin	-13,262.02%	-40,354.33%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GANX	$83.70M	18	3.7	3.0	5.0	6.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Gain Therapeutics Inc trades at $1.76. Our Smart Value Score of 18/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -12.79, it sits in the distress.

Frequently asked questions

What is Gain Therapeutics Inc's stock price?

Gain Therapeutics Inc (GANX) trades at $1.76.

Is Gain Therapeutics Inc overvalued?

Smart Value Score 18/100 (Grade F, Strong Sell).

What is the price target of Gain Therapeutics Inc (GANX)?

The analyst target price is $7.60, representing +331.8% upside from the current price of $1.76.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-12.79 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

gaintherapeutics.com

Quick metrics

P/S ratio255.50x

ROE-155.70%

Beta0.11

50D MA$2.16

200D MA$2.17

Shares out0.04B

Float0.04B

Short ratio—

Avg volume0.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GANX vs LLY →GANX vs JNJ →GANX vs ABBV →Stock screener →